---

Attention-Deficit/Hyperactivity Disorder (ADHD): A Complete Guide

---

1. Historical Background

• 1902 — George Still: British pediatrician Sir George Still described 43 children with "an abnormal defect of moral control" — persistent inability to inhibit behavior despite intact intellect and intact understanding of social norms. These children were impulsive, inattentive, and hyperactive. This is the first formal clinical description recognizable as ADHD.
• 1920s — Post-Encephalitic Behavioral Syndrome: Following the 1918 influenza pandemic and encephalitis lethargica epidemic, many children developed hyperactive, disinhibited, impulsive behavior. This led to the concept of "minimal brain damage" — the idea that hyperactivity and inattention reflected underlying brain injury.
• 1930s — Charles Bradley: In 1937, Bradley discovered that benzedrine (an amphetamine) dramatically improved behavior and school performance in institutionalized children — the first evidence of stimulant efficacy.
• 1960s — DSM-II: The condition was termed "Hyperkinetic Reaction of Childhood" — focus was on hyperactivity as the cardinal symptom.
• 1980 — DSM-III: A major conceptual shift: Attention Deficit Disorder (ADD) with or without hyperactivity — inattention was recognized as the core symptom, not just hyperactivity. This reflected the work of Virginia Douglas, who showed that sustained attention deficits, not mere hyperactivity, defined the disorder.
• 1987 — DSM-III-R: Renamed to Attention-Deficit Hyperactivity Disorder (ADHD) as a single diagnostic category.
• 1994 — DSM-IV: Three subtypes introduced: Predominantly Inattentive, Predominantly Hyperactive-Impulsive, and Combined Type. Also recognized that ADHD could persist into adulthood in up to 30% of cases.
• 2013 — DSM-5: Major updates — age of onset raised from 7 to 12 years; subtypes replaced by "presentations"; adults and adolescents ≥17 years require only 5 (not 6) symptoms; ADHD now co-diagnosable with autism spectrum disorder (previously excluded).

---

2. Definition

• Interferes with functioning or development
• Is inconsistent with the developmental level
• Is present in at least two settings (e.g., home and school/work)
• Has its onset before age 12 years
• Is not better explained by another mental disorder

---

3. Epidemiology

---

4. Etiology and Pathophysiology

4.1 Genetic Factors

• Heritability is ~75–80% — among the highest of any psychiatric disorder
• Family studies: First-degree relatives of ADHD children have 2–8× increased risk
• Twin studies: Monozygotic concordance ~50–80%; dizygotic ~30–40%
• Candidate genes implicated:
  • Dopamine receptor genes: DRD4 (especially the 7-repeat allele), DRD5
  • Dopamine transporter gene: DAT1/SLC6A3
  • Norepinephrine transporter: NET1/SLC6A2
  • Synaptosomal-associated protein: SNAP25
  • COMT (catechol-O-methyltransferase) — involved in prefrontal dopamine metabolism
• Rare copy number variants (CNVs) — particularly deletions at chromosomes 16p13.11 and 22q11.2
• ADHD shares genetic risk with autism, schizophrenia, and bipolar disorder

4.2 Neurobiological Mechanisms — Dopamine & Norepinephrine

• The prefrontal cortex (PFC) governs executive function, working memory, inhibitory control, and sustained attention
• PFC function depends critically on optimal dopamine (DA) and norepinephrine (NE) tone
• In ADHD, there is hypofunction of dopaminergic and noradrenergic neurotransmission in the PFC
• Dopamine: Acts via D1 receptors in PFC — too little or too much DA impairs working memory (an inverted U-shaped dose-response curve)
• Norepinephrine: Acts via α2A receptors in PFC to strengthen "signals" and reduce "noise" — NE deficiency leads to distractibility and poor sustained attention
• Stimulant medications work by increasing synaptic DA and NE — primarily by blocking reuptake transporters (methylphenidate) or promoting release (amphetamines)

4.3 Neuroimaging Findings

• Structural MRI: Children with ADHD have slightly smaller total brain volumes, with delays in cortical maturation (particularly prefrontal, parietal, and temporal cortices)
• The caudate nucleus and cerebellar vermis show reduced volume
• Cortical thinning in frontal lobes
• Delayed cortical maturation — the ADHD brain follows the same trajectory as controls but ~2–3 years behind
• Functional MRI: Reduced activation of the right prefrontal cortex, striatum, and anterior cingulate cortex during tasks requiring inhibitory control
• Default mode network (DMN) shows abnormal suppression during task performance (normally, DMN deactivates during focused tasks) — excessive DMN activity in ADHD = mind-wandering

4.4 Neuropsychological Profile

• Executive function deficits — the most consistent finding:
  • Impaired response inhibition (Stop-Signal Task)
  • Working memory deficits
  • Impaired cognitive flexibility
  • Poor planning and organizational skills
• Impaired sustained attention on Continuous Performance Tasks (CPT/TOVA)
• Intra-individual variability in reaction times — a hallmark feature
• Normal IQ in most cases, but low scores on Wechsler subtests sensitive to attention: Digit Span, Coding, Arithmetic, Symbol Search
• Frontal lobe / executive functioning tasks most affected: spatial working memory, stop-task, Stroop

4.5 Environmental Risk Factors

• Prenatal exposures:
  • Maternal smoking during pregnancy (strong association — nicotinic receptors involved in dopaminergic development)
  • Alcohol use in pregnancy
  • Prenatal stress
  • Lead exposure (even low-level prenatal/postnatal lead)
• Perinatal factors: Prematurity, low birth weight, hypoxic-ischemic encephalopathy
• Postnatal: Severe early psychosocial deprivation (e.g., institutional orphanage rearing)
• Diet: High sugar diet — controversial; refined foods and additives (e.g., Feingold hypothesis) — modest evidence; omega-3 fatty acid deficiency has some supporting data
• Screen time: Excessive early screen exposure associated (causality debated)

---

5. DSM-5 Diagnostic Criteria

Criterion A — Symptoms (must have ≥6 in children <17; ≥5 in adolescents ≥17 and adults)

1. Often fails to give close attention to details or makes careless mistakes
2. Often has difficulty sustaining attention in tasks or play
3. Often does not seem to listen when spoken to directly
4. Often does not follow through on instructions; fails to finish tasks
5. Often has difficulty organizing tasks and activities
6. Often avoids, dislikes, or is reluctant to engage in tasks requiring sustained mental effort
7. Often loses things necessary for tasks (keys, pencils, books)
8. Often easily distracted by extraneous stimuli
9. Often forgetful in daily activities

1. Often fidgets with hands/feet or squirms in seat
2. Often leaves seat in situations where remaining seated is expected
3. Often runs about or climbs in situations where it is inappropriate
4. Often unable to play quietly
5. Often "on the go," acting as if "driven by a motor"
6. Often talks excessively
7. Often blurts out answers before questions are completed
8. Often has difficulty waiting their turn
9. Often interrupts or intrudes on others

Criterion B

Criterion C

Criterion D

Criterion E

---

6. Presentations/Subtypes

---

7. Clinical Features Across the Lifespan

Infancy & Toddlers

• Excessive activity in the crib, poor sleep, excessive crying
• High temperamental difficulty
• Note: False-positive rate is high; diagnosis requires caution

Preschool (3–5 years)

• Hyperactive and impulsive symptoms are most prominent and reliable
• Peak around ages 4–5 years
• Running, climbing, unable to sit for meals or storytime
• Frequent temper tantrums, accidents

School Age (6–12 years) — Classic Presentation

• Inattention: Fails to finish tasks, loses school supplies, careless errors, easily distracted
• Hyperactivity: Cannot stay in seat, blurts out answers, intrudes on peers
• Impulsivity: Acts before thinking, accident-prone, poor peer relationships
• Academic underperformance despite often-average intelligence
• Low self-esteem, frustration
• Comorbid learning disorders, oppositional defiant disorder (ODD), anxiety

Adolescence

• Hyperactivity diminishes (replaced by subjective restlessness, feelings of being "driven")
• Inattention and impulsivity persist
• Risk of: school dropout, delinquency, substance use, driving accidents
• Peer relationship difficulties, emotional dysregulation prominent

Adulthood

• Global prevalence ~2.5–4%; many first diagnosed as adults
• Symptoms "internalized" — restlessness rather than overt hyperactivity
• Manifestations: disorganization, procrastination, difficulty sustaining employment, relationship difficulties, emotional dysregulation (mood lability, low frustration tolerance), impulsive decision-making
• Higher rates of divorce, job loss, legal problems, accidents
• Significant overlap with depression, anxiety, bipolar disorder

---

8. Comorbidities

---

9. Diagnosis and Evaluation

1. Detailed history: Symptom onset, duration, settings, functional impairment
2. Multiple informants: Parent, teacher, self-report (child/adolescent/adult)
3. Standardized rating scales:
   • Conners' Rating Scales (parent, teacher, self-report)
   • Vanderbilt Assessment Scale
   • ADHD Rating Scale-5
   • Wender Utah Rating Scale (WURS) — for retrospective adult diagnosis
   • DIVA-5 (Diagnostic Interview for ADHD in Adults) — gold standard for adults
4. Physical examination: Rule out medical causes (thyroid disease, seizure disorder, hearing/vision problems)
5. Neuropsychological testing: Not mandatory but helpful when learning disability suspected; reveals executive function deficits
6. EEG / qEEG: Not routine; qEEG patterns (increased theta/alpha power, decreased beta) may support diagnosis but lack sufficient specificity
7. QbTest: Objective continuous performance + motion tracking test; being evaluated as adjunct (NICE 2023)

• Anxiety disorders (can cause inattention and restlessness)
• Depression (cognitive slowing mimics inattention)
• Sleep disorders (sleep deprivation causes ADHD-like symptoms)
• Learning disabilities
• Autism spectrum disorder
• Bipolar disorder
• Substance use
• Thyroid dysfunction
• Seizure disorders

---

10. Prognosis

---

11. Pharmacological Treatment

First-Line: Psychostimulants

---

11.1 Methylphenidate (MPH)

• Provide coverage throughout the school/work day
• Improve adherence
• Reduce abuse potential and diversion
• Eliminate need for midday school dosing

• Appetite suppression (very common) → weight loss; give after meals
• Insomnia — give earlier in the day; use IR booster not later than 3 PM
• Blood pressure and heart rate elevation (moderate increases)
• Growth deceleration — long-term use associated with modest reduction in height and weight
• Headache, abdominal pain, irritability (especially rebound)
• Tics — may exacerbate pre-existing tics (less than amphetamines)
• Mood suppression — "zombie effect" at high doses
• Rebound — irritability as medication wears off

---

11.2 Amphetamines

• Designed to resist abuse (cannot be snorted or injected effectively)
• Network meta-analyses found it more effective than methylphenidate
• Effective in preschoolers (though not licensed for this age group)
• Approved for ADHD with comorbid binge eating disorder
• Associated with improved outcomes in ADHD with comorbid amphetamine/methamphetamine use disorders

• Higher risk of diversion and misuse (dexamfetamine > methylphenidate)
• Slightly more cardiovascular effect
• More pronounced appetite suppression
• More insomnia

---

11.3 Cardiovascular Monitoring

• Baseline workup: Physical exam, BP, pulse, weight, height
• ECG before initiation if family history of cardiac disease or risk factors
• Quarterly monitoring: Height, weight, BP, pulse
• Annual physical exam

---

Second-Line / Non-Stimulant Medications

11.4 Atomoxetine (Strattera)

• No abuse potential → preferred when diversion/misuse is a concern
• Can treat comorbid anxiety
• 24-hour coverage with once-daily dosing
• Can treat tics (unlike stimulants which may worsen tics)
• Less insomnia

• Less effective than stimulants
• Slow onset — full effect takes 4–6 weeks (vs. hours for stimulants)
• Suicidality warning (black box): Increased risk of suicidal thinking in children and adolescents — monitor closely
• Hepatotoxicity: Rare but serious liver injury reported — warn parents of jaundice, RUQ pain, dark urine
• Side effects: Nausea, decreased appetite, fatigue, irritability, sexual dysfunction in adults, urinary retention

---

11.5 Alpha-2 Adrenergic Agonists

---

• α2A selective agonist — more PFC-targeted, less sedating than clonidine
• Licensed for ADHD in children in UK and US
• Broadly as effective as atomoxetine
• Particularly useful: Tics, anxiety, aggression, sleep disturbance, oppositional symptoms comorbid with ADHD
• Side effects: Sedation (often mild), hypotension, bradycardia, headache
• Do not stop abruptly — risk of rebound hypertension

• Less selective α2 agonist — more sedating
• Widely used in USA but not licensed in most countries
• Useful for tics, sleep disturbance, and aggression comorbid with ADHD
• Side effects: Significant sedation, hypotension, bradycardia, dry mouth
• Same caution: do not stop abruptly

---

11.6 Viloxazine Extended-Release (Qelbree)

• Selective NE reuptake inhibitor with additional serotonergic modulation
• FDA-approved for ADHD in children ≥6 years and adults (2021)
• Not a controlled substance
• Effective in clinical trials; approved in USA
• Mentioned in both Maudsley and Kaplan & Sadock as a newer non-stimulant option

---

11.7 Bupropion

• Dopamine and norepinephrine reuptake inhibitor + nicotinic antagonist
• Evidence of efficacy in ADHD in multiple trials; also treats comorbid depression
• Not FDA-approved specifically for ADHD (off-label)
• Useful when ADHD + depression or ADHD + nicotine dependence coexist
• Lowers seizure threshold — avoid in eating disorders, prior seizures, abrupt alcohol withdrawal

---

11.8 Tricyclic Antidepressants (TCAs — imipramine, desipramine)

• Historical second-line agents; some evidence of efficacy
• Not recommended in clinical practice due to cardiac toxicity (QTc prolongation), fatal overdose risk, multiple side effects
• Only considered as last resort

---

11.9 Modafinil

• Wake-promoting agent that works on dopamine, NE, histamine pathways
• Evidence of utility in children with ADHD but not effective in adults with ADHD
• Not FDA-approved for ADHD; off-label use

---

11.10 Second-Generation Antipsychotics

• Not recommended for ADHD (per Maudsley and consensus guidelines)
• May reduce hyperactivity in autism spectrum disorder
• Metabolic side effects, tardive dyskinesia risk — not warranted for ADHD

---

Treatment Algorithm Summary

Step 1: ADHD diagnosis confirmed + psychoeducation + environmental modifications
         ↓
Step 2: First-line — Extended-release stimulant
         • Methylphenidate ER (children)
         • Lisdexamfetamine or methylphenidate (adults)
         ↓ [If inadequate response after adequate trial]
Step 3: Switch to alternative stimulant class (MPH → amphetamine or vice versa)
         ↓ [If stimulants contraindicated, not tolerated, or diversion concern]
Step 4: Atomoxetine OR Guanfacine ER
         ↓ [Augmentation if partial response]
Step 5: Combine stimulant + alpha-2 agonist; or add behavioral interventions
         ↓ [Complex cases]
Step 6: Bupropion, viloxazine, specialist referral

---

12. Non-Pharmacological Treatment

---

12.1 Psychoeducation

• The foundation of all ADHD management
• For child, parents, teachers, and often employers
• Content covers: nature of ADHD, neurobiological basis, dispelling myths (laziness, bad parenting), realistic expectations, impact across settings, long-term outlook
• Reduces guilt, blame, stigma
• Improves treatment adherence

---

12.2 Parent Training in Behavior Management (PTBM)

• Most evidence-based non-pharmacological intervention for children with ADHD
• Core programs: Defiant Children (Barkley), Incredible Years, Triple P, Parent-Child Interaction Therapy (PCIT)
• Teaches parents to:
  • Use positive reinforcement consistently and specifically
  • Use appropriate consequences (time-out, privilege removal)
  • Establish clear, predictable routines and household structure
  • Manage antecedents (environmental modifications to prevent problems)
  • Communicate effectively with child's school
  • Manage own emotional reactions to child's behavior
• Evidence: Strongly reduces oppositional behavior, improves parent-child relationship, reduces parental stress

---

12.3 Behavioral Therapy / Behavior Modification

• Based on operant conditioning principles
• Applied in home and school settings
• Key techniques:
  • Token economy systems: Points/stickers earned for target behaviors → exchanged for rewards
  • Response cost: Loss of tokens/privileges for problem behaviors
  • Daily Report Cards (DRC): School-home behavioral monitoring with consistent reinforcement
  • Contingency management: Immediate, consistent consequences for behavior (ADHD children are particularly sensitive to immediacy — delayed consequences are ineffective)
  • Time-out from positive reinforcement
• The MTA Study (NIMH-sponsored, n=579 children with ADHD) is the landmark trial:
  • Four arms: medication alone, intensive behavioral treatment, combination, community care
  • At 14 months: Medication alone and combination were superior to behavioral treatment alone for core ADHD symptoms
  • However, combination therapy was superior to medication alone for comorbid anxiety, academic functioning, parent-child relationships, and social skills
  • Combined treatment requires less medication for equivalent effect
  • Long-term follow-up: Differences between groups diminished over time, underscoring importance of comprehensive management

---

12.4 Cognitive-Behavioral Therapy (CBT)

• More useful in adolescents and adults than young children (requires metacognitive capacity)
• Targets:
  • Organizational skills (calendar use, breaking tasks into steps, decluttering)
  • Time management (time estimation, setting alarms, prioritization)
  • Procrastination — behavioral activation strategies
  • Emotional dysregulation — mindfulness, cognitive restructuring
  • Impulsivity — stop-think-act sequences
  • Negative self-beliefs — challenging ADHD-related core beliefs ("I'm stupid," "I'm a failure")
• CBT in adults with ADHD has reasonable evidence when combined with medication

---

12.5 Social Skills Training

• Group-based intervention targeting peer relationship difficulties
• Teaches: turn-taking, active listening, conflict resolution, reading social cues, appropriate conversational skills
• Most beneficial when practiced in naturalistic settings (school, after-school programs)
• Evidence: Modest benefit in isolation; better as part of comprehensive program

---

12.6 Academic and School-Based Interventions

• IEP/504 Plan (USA) — legal framework for school accommodations
• Specific accommodations:
  • Extended time on tests
  • Preferential seating (front of class, away from distractions)
  • Chunked assignments (break into smaller steps)
  • Frequent breaks
  • Organization aids (assignment notebooks, color-coded folders)
  • Reduced homework load when appropriate
  • Separate testing environment
  • Use of technology (e.g., text-to-speech, speech-to-text)
• Resource room / special education support for comorbid learning disabilities
• Teacher education: Understanding ADHD, consistent classroom management, positive behavioral supports

---

12.7 Exercise and Physical Activity

• Growing evidence that aerobic exercise improves attention, executive function, and mood in ADHD
• A 2025 systematic umbrella review (Singh et al., PMID 40049759, Br J Sports Med) confirmed exercise improves cognition, memory, and executive function
• Mechanisms: Exercise acutely increases DA and NE in PFC; promotes neuroplasticity and BDNF
• Practical recommendations: 30–60 minutes of moderate-intensity aerobic exercise daily (running, swimming, cycling, martial arts)
• Martial arts, yoga, and team sports are particularly beneficial — add structure, focus, self-regulation

---

12.8 Dietary Interventions

• Elimination diets (Feingold diet — removing artificial colors, additives): Modest benefit in a subgroup, effect size is small
• Omega-3 fatty acid supplementation: Multiple studies show modest improvement in ADHD symptoms; safe, low-risk adjunct; EPA ≥720 mg/day in supplementation studies
• Avoiding excessive sugar and processed food: Reasonable but not evidence-based as specific ADHD treatment
• Iron, zinc, magnesium supplementation: Some evidence of deficiency in ADHD; supplementation in deficient children shows modest benefit
• Cannot replace pharmacotherapy or behavioral treatment

---

12.9 Neurofeedback

• Teaches patients to self-regulate brain activity using real-time EEG feedback
• Standard protocols target: increasing sensorimotor rhythm (SMR) or beta, decreasing theta waves
• Controversy: A 2025 systematic review and meta-analysis (Westwood et al., PMID 39661381, JAMA Psychiatry 2025) found that:
  • Neurofeedback showed improvements in probably blinded assessments and active control comparisons
  • However, effects were not robust in fully blinded (double-blind) studies
  • Current evidence does not support neurofeedback as a stand-alone treatment
• Clinical position: Consider as adjunct when standard treatments are insufficient or refused; not first-line

---

12.10 Mindfulness-Based Interventions

• Adapted mindfulness programs for children and adults with ADHD (e.g., Mindfulness-Based Cognitive Therapy for ADHD)
• Targets: Attentional control, emotional regulation, impulsivity
• Growing evidence in adults; smaller evidence base in children
• Mechanisms: Improves prefrontal regulation of attention and emotion
• Accessible, low cost, no side effects — reasonable adjunct

---

12.11 Coaching

• ADHD coaching (distinct from therapy): Practical skills-based support
• Targets: Time management, goal-setting, accountability, organization, task initiation
• Popular in adults; increasingly recognized in adolescents
• Not a licensed profession with standardized training — quality varies

---

12.12 Environmental and Lifestyle Modifications

• Sleep hygiene: ADHD and sleep disorders are tightly linked; treat sleep problems aggressively (consistent bedtimes, no screens before sleep, guanfacine may help)
• Structured daily routines: Predictability reduces ADHD-related dysfunction
• Reduce environmental distractions: Homework in quiet, low-stimulation environment
• Minimize transition-heavy schedules
• Music: White noise or instrumental music during homework may help some children with ADHD focus

---

13. Special Populations

Children <6 Years (Preschool ADHD)

• Behavioral parent training first-line (AAP guideline)
• Medication only if behavioral treatment fails and symptoms are severe/impairing
• Methylphenidate at lower doses if used (lisdexamfetamine not licensed)

Adolescents

• Increased risk of stimulant diversion — modified-release preparations preferred
• Address substance use risk; ADHD treatment does not increase SUD risk — it may be protective
• Transition planning from pediatric to adult services critical

Adults

• First-time diagnosis increasing rapidly
• DIVA-5 structured interview recommended
• Lisdexamfetamine or methylphenidate ER as first-line
• Non-stimulants preferred when: substance misuse history, bipolar disorder, psychosis, diversion risk
• Stimulant medication may worsen bipolar disorder and psychosis — screen carefully before prescribing

Pregnancy

• ADHD in pregnancy requires individualized risk-benefit assessment
• Data on safety of ADHD medications in pregnancy are limited
• Non-pharmacological approaches preferred when possible
• Some pregnancies may require continuation of medication if symptoms are severely impairing

ADHD + Substance Use Disorders

• ADHD markedly increases risk of SUD
• Treating ADHD effectively may be protective against SUD
• Prefer non-stimulant medications (atomoxetine) or lisdexamfetamine (hard to abuse)
• Avoid immediate-release stimulants
• Behavioral treatment essential

---

14. Recent Evidence (2024–2025)

---

15. Quick Reference Summary

---